X0609 4 2026-07-28 0001607678 Viking Therapeutics, Inc. VKTX 0001264949 ZANTE GREG false C/O VIKING THERAPEUTICS, INC. 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 false true false false Chief Financial Officer false Common Stock, par value $0.00001 per share 2026-07-28 4 A false 31667 0 A 233421 D Common Stock, par value $0.00001 per share 2026-07-29 4 S false 21217 33.4704 D 212204 D The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal. Includes 11,055 shares acquired on May 20, 2024 pursuant to the Issuer's 2014 Employee Stock Purchase Plan and 808 shares acquired on May 20, 2026 pursuant to the Issuer's 2024 Employee Stock Purchase Plan These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.30 to $33.805, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote. /s/ Michael Morneau, as Attorney-in-Fact 2026-07-29